

B

**SUMMARY**

**510(k) SUMMARY OF SAFETY AND EFFECTIVENESS  
GLASS LOSS OF RESISTANCE SYRINGE**

Regulatory Affairs Contact:	Muhamad Ansari Busse Hospital Disposables PO Box: 11067 75 Arkay Dr. Hauppauge NY 11788	JAN 22 2007
Telephone:	631-435-4711 Ext: 254	
Fax:	631-435-2849	
Date Summary Revised:	January 17, 2007	
Product Trade Name:	Glass Loss of Resistance Syringe	
Common Name:	Conduction Anesthetic	
Classification:	Class II, 21 CFR <u>868.5140</u>	
Product Code:	CAZ	
Predicate Device:	BD Glass Loss of Resistance Syringe – (Pre-Amendment Device)	
Device Description:	The Glass Loss of Resistance Syringe is a single use device, which is sold as sterile individually packaged and sterile packaged inside a kit/procedure tray. The syringe will be available in luer lock and luer slip tip.	
Intended Use:	The Glass Loss of Resistance Syringe is intended for use in conjunction with an epidural needle, to verify the needle tip placement in the epidural space by the loss of Resistance technique, it will be filled with air and/or saline during use. The loss of Resistance Syringe is not intended for injection or aspiration. The syringe will be sold sterile individually packaged, and as part of a sterile kit.	

# B

## 510(k) SUMMARY OF SUBSTANTIAL EQUIVALENCE

Summary of Testing: All materials used in the fabrication of the specialty needles were evaluated through biological qualification safety tests. The biocompatibility tests performed were L929 Men Elution Test, Intracutaneous Injection Test, Systemic Injection Test, Salmonella Typhimurium and Escherichia Coli Reverse Mutation Assay, Hemolysis – Rabbit Blood Test, and Kligman Maximization Test. These materials have met the testing requirements and were found to be acceptable for the intended use.

### Technological Characteristics:

[21 CFR 807.92(a)(6)]

The subject device has the same Technological Characteristics as a legally marketed predicate device.

### Conclusion:

[21 CFR 807.92(b)(3)]

The above statements are accurate representations of the device Busse intends to market. All data and information submitted in this premarket notification is truthful and accurate and no material fact has been omitted.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

JAN 22 2007

Mr. Muhamad Ansari  
Director of Regulatory Affairs  
Busse Hospital Disposables, Incorporated  
P.O. Box 11067  
75 Arkay Drive  
Hauppauge, New York 11788

Re: K063018

Trade/Device Name: Glass Loss of Resistance Syringe  
Regulation Number: 21 CFR 868.5140  
Regulation Name: Anesthesia Conduction Kit  
Regulatory Class: II  
Product Code: CAZ  
Dated: December 12, 2006  
Received: December 15, 2006

Dear Mr. Ansari:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Chiu Lin, Ph.D.  
Director  
Division of Anesthesiology, General Hospital,  
Infection Control and Dental Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

**INDICATIONS FOR USE**

510(k) Number (if known):     K063018    

Device Name: Glass Loss of Resistance Syringe.

Indication for Use: The Glass Loss of Resistance Syringe is intended for use in conjunction with an epidural needle, to verify the needle tip placement in the epidural space by the loss of Resistance technique; it will be filled with air and/or saline during use. The loss of Resistance Syringe is not intended for injection or aspiration. The Syringe will be sold sterile individually packaged, and as part of a sterile kit.

Prescription Use     x      
(Per 21 CFR 801Subpart D)


AND/OR

Over-The-Counter Use       
(Per 21 CFR 801Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)



Susan Brown, General Manager  
Medical Devices

    K063018